Background {#Sec1}
==========

Randomized and observational studies have shown that exercise capacity is a strong predictor of cardiovascular prognosis. Even when fully revascularized, patients with stable coronary artery disease (CAD) and normal left ventricular ejection fraction (LVEF) have lower than expected exercise capacity \[[@CR1]\]. Patients with visceral obesity or the metabolic syndrome also have impaired exercise capacity \[[@CR2]\]. The limiting factors of exercise capacity in these clinical entities is unclear.

Reduced coronary microvascular function has emerged as a strong predictor of poor prognosis. In patients with CAD, in patients with diabetes \[[@CR3]\] and in subjects with cardiometabolic risk factors, such as hypertension \[[@CR4]\] and visceral obesity \[[@CR5]\], coronary microvascular function is impaired. Coronary microvascular dysfunction has also been linked to impaired exercise capacity. We have previously found that coronary flow reserve (CFR) as a measure of coronary microvascular function is strongly associated with exercise capacity in CAD and chronic heart failure \[[@CR6]\]. We have also described an association between insulin sensitivity and CFR in heart failure patients \[[@CR7]\]. An understanding of how these important markers interact in explaining limitations to exercise capacity is lacking. This study explores whether measures of glucose metabolism and body composition contribute to the previously observed link between coronary microvascular function and exercise capacity in overweight non-diabetic patients with CAD.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

This study is based on baseline data from the randomized, controlled CUT-IT trial comparing the cardiovascular effects of a weight loss facilitated using a low energy diet (LED) and aerobic interval training in overweight non-diabetic patients with CAD. The study is in compliance with the Declaration of Helsinki and has been approved by the Regional Ethics Committee of the Capital Region in Denmark (no H-4-2010-146) and the Danish Data Protection Agency (no 2011-41-6313). The trial is registered at clinicaltrials.gov (NCT01724567). Informed written consent for participation in the study was obtained from all participants. The inclusion criteria and study design have been published previously \[[@CR8], [@CR9]\]. In summary, inclusion criteria were CAD diagnosed more than 6 months prior to inclusion, age 45 -- 75 years, body mass index (BMI) 28--40 kg/m2 and no diabetes. A subgroup of the patients (*n* = 30) were included in a previously reported analyses of association between CFR and VO~2~peak \[[@CR6]\]. The present analyses expand those results to a larger patient group and aims at gaining mechanistic insight through including detailed data on body composition and glucose metabolism.

Cardiopulmonary exercise test {#Sec4}
-----------------------------

The participants underwent a cardiopulmonary exercise test (CPET) using an upright bicycle ergometer (Via Sprint 150P, Ergoline, Bitz, Germany) with breath-by-breath gas exchange measurement of oxygen consumption and CO~2~ production (Jaeger, Masterscreen CPX, Cardinal Health, Würzburg, Germany) at the screening and the baseline visit. The screening visit was used to familiarize the participant to the test and to ensure that the optimal exercise protocol was used at baseline. The data used in the present study is the baseline test. All participants were encouraged to continue until exhaustion and a satisfactory effort was anticipated when VO~2~ and/or heart rate failed to increase with further increases in workload or peak respiratory exchange ratio (RER) (VCO~2~/VO~2~) exceeded 1.05. VO~2~peak and RER were calculated as the means of the six highest consecutive five-second measurements before exercise termination. VO~2~peak was adjusted to both total body weight (VO~2~peak~BW~) (mL/kg body weight/min) and fat free mass (FFM) (VO~2~peak~FFM~) (mL/kg FFM^(2/3)^/min) \[[@CR10]\]. Predicted VO~2~peak was calculated using the equation for sedentary individuals as proposed by Wassermann and Hansen \[[@CR11]\].

Body composition {#Sec5}
----------------

The participants' fasting-state body mass, hip and waist circumference were measured by standardized procedures \[[@CR9]\]. Body composition, including fat mass and fat free mass, was assessed using whole body dual-energy X-ray absorptiometry (DEXA) (Lunar DPX-IQ, GE Lunar Corp, Madison, WI). The ratio of central to peripheral distribution of body fat was estimated by dividing the body fat in the DXA trunk region of interest (ROI) by the ROIs that encompass the arms, hips and legs \[[@CR12]\]. Visceral abdominal adipose tissue was determined by magnetic resonance imaging (MRI) in a subgroup (*n* = 37). MRI measurements and analyses were performed using the Achieva 3.0 T MRI system and the Philips ViewForum workstation (Philips Medical Systems, Best, the Netherlands) and a sense cardiac coil. Images were obtained by a fast T1w turbo field echo (TFE) MR sequence in the transverse plane (TFE sequence, TFE factor = 136, TR = 10 ms, TE = 2.3 ms, FOV = 480 mm, respiratory trigger compensation with trigger delay of 1000 ms). A transverse slice (thickness: 10 mm) was acquired in the supine position in the middle of the third lumbar vertebra and visceral fat was measured.

Oral glucose tolerance test {#Sec6}
---------------------------

A 3 hour oral glucose tolerance test (OGTT) with measurement of plasma glucose-, insulin- , and C-peptide levels was performed. After a 10 hour overnight fast an oral glucose load of 75 g dissolved in 300 ml water was administered within 2 minutes. Plasma samples were obtained at −10,0,10,20,30,45,60,75,90,105,120,150 and 180 minutes. Blood samples were immediately cooled on ice and centrifuged for 10 minutes (3500 rpm, Universal 320R, Hettich Centrifugen, Tuttlingen, Germany). Glucose analysis was performed using an YSI 2300 STAT Plus Glucose and Lactate Analyser (YSI incorporated, Yellow Springs, OH, USA). Enzyme-linked immunosorbent assay (ELISA) was used to determine C-peptide and insulin (pmol/l, Immulite 2000, Siemens Healthcare Diagnostics, LA, Califonia, USA). Glycated hemoglobin HbA1c was estimated by high performance liquid chromatography.

Based on the OGTT the following glucose metabolic parameters were calculated:

Fasting plasma glucose (FPG, mmol/L) and fasting plasma insulin (FPI, pmol/L) were calculated as the average of plasma values at time −10 and 0 minutes. Glucose tolerance was defined as the 2 hour plasma glucose concentration (2 h-PG). The composite measure of whole body insulin sensitivity (ISI~Composite~) \[[@CR13]\] and the homeostatis model assessment of hepatic insulin resistance (HOMA-IR) \[[@CR14]\] were determined as follows:$$\documentclass[12pt]{minimal}
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                \begin{document}$$ \overline{I} $$\end{document}$ is mean plasma glucose and insulin, respectively, measured during the OGTT at 0, 30, 60, 90 and 120 minutes. 1/HOMA-IR was used as an estimation of insulin sensitivity (ISI~HOMA~).

Prehepatic insulin secretion rates (ISR) (pmol/kg/min) were calculated from plasma C-peptide concentrations using the ISEC (Insulin SECretion) computer program \[[@CR15]\]. The method is based upon the assumptions that insulin and C-peptide are co-secreted in equimolar amounts by the pancreas and that C-peptide is not cleared by the liver. β-Cell secretion in response to changes in glucose concentration during the OGTT expresses the efficacy by which changes in plasma glucose concentrations stimulate insulin secretion. The relationship between plasma glucose concentrations and ISR during the OGTT was evaluated by cross-correlation analysis and the slope of the regression lines (β~total~), which express the change in insulin secretion per unit change in glucose concentration, was used as a measure of β-cell responsiveness. Disposition index (Di) was calculated as a measure of β-cell function adjusted for insulin sensitivity \[[@CR16]\]:$$\documentclass[12pt]{minimal}
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Coronary flow reserve and echocardiography {#Sec7}
------------------------------------------

All participants underwent a complete transthoracic echocardiography using a Vivid E9 (GE Medical Systems, Inc., Horten, Norway). Left ventricular end-diastolic volume (EDV), end-systolic volume (ESV) and left ventricular ejection fraction (LVEF) were calculated using the biplane Simpson method. EDV and ESV were corrected for body surface area using the Mosteller formula \[[@CR17]\]. CFR was measured using a high frequency S6 transducer (GE Medical Systems, Inc., Horten, Norway). All participants were instructed to abstain from caffeine 24 hours prior to the examination and the use long acting nitroglycerin was suspended for 24 hours. Starting in a modified apical 5-chamber view, which intersected the anterior wall, and using color Doppler with a low Nyquist limit, the left anterior descending artery (LAD) was located in its distal path. If unsuccessful the LAD was located mid-distally in the interventricular sulcus using a low short-axis view. Hyperemia was induced by infusion of dipyridamole (0.84 mg/kg over 6-minutes) or adenosine (0.14 mg/kg/min for 2 minutes) . CFR was calculated as the ratio between peak coronary flow velocity at rest and during hyperemia. We have previously reported inter and intra-observer variability of repeated off-line CFR readings with within-subject coefficient of variation (CV) of 5.5 % (*n* = 39) and 7.5 % (*n* = 10), respectively \[[@CR18]\].

Statistics {#Sec8}
----------

Unless stated otherwise all values are expressed as median and interquartile range for continuous variables and as number and percentage for categorical variables. Continuous variables were compared using Student's t-test and differences in categorical variables were assessed by χ^2^ test. The Pearson product--moment correlation coefficient was used to estimate the associations between continuous variables and multivariable linear regression with standardized coefficients (SC) were performed to identify independent predictors of VO~2~peak. The multivariable model included age and gender (fixed) and tested each covariate based on associations from univariate analyses as specified below. Variables with p \< 0.10 were retained in the multivariable model. The significance level was set to p \< 0.05. All analyses were done using Stata 13.1 software (StataCorp, College Station, TX, USA).

Results {#Sec9}
=======

We recruited 70 participants without significant stenosis of the LAD. Of these 65 participants completed a satisfactory CPET and had a successful CFR measurement. In two patients the image quality was too poor to assess CFR and three patients did not fulfill the criteria for a satisfactory CPET. Patient characteristics are presented in Table [1](#Tab1){ref-type="table"}. Patients were primarily male and had well-regulated blood pressures. Fifty-seven (87.7 %) participants had previously been revascularized, and none had ischemic changes in ECG during CPET. Thirteen (20 %) participants reported angina only during strenuous or prolonged physical activity while the remaining participants were asymptomatic. Median BMI was 31.3 (29.7-33.7) and forty-seven (72 %) of the patients had prediabetes defined as either impaired glucose tolerance (FPG \< 7.0 mmol/L and 7.8 ≤ 2hPG \< 11.1 mmol/L) or impaired fasting glucose (FPG 5.6-6.9 mmol/L).Table 1Patient characteristics. Values are median (IQ range) or number (%)Patient characteristics *n* = 65Median/numberIQ range/percentageAge63(58--67)Male Sex54(83.1 %)Fat percentage (%)34.0(30.5--38.6)BMI (kg/m^2^)31.3(29.7--33.7)Prediabetes47(72.3 %)Predicted VO~2~peak (%)93.9 %(84.6--109.2)VO~2~peak~BW~ (ml/min/kg)20.9(17.3--25.1)VO~2~peak~FFM~ (ml/min/kg FFM^(2/3)^)127(108.8--145.6)Respiratory exchange ratio1.19(1.16--1.26)ICD2(3.1 %)Systolic blood pressure (mmHg)127(118--135)Diastolic blood pressure (mmHg)72(67--79)Medication* -Beta-blockers*\
* -Statins*\
* -ASA or/and Clopidogrel*\
* -Diuretics*\
* -ACE-inhibitors*34\
63\
62\
21\
29(52.3 %)\
(96.9 %)\
(95.4 %)\
(32.3 %)\
(44.6 %)Atrial fibrillation3(4.6 %)Left ventricular ejection fraction (%)54(46--59)Ischemic etiology* -Previous PCI or CABG*\
* Involving LAD*\
* -Previous myocardial infarction*\
* Involving LAD*57\
36\
35\
15(87.7 %)\
(55.4 %)\
(53.9 %)\
(23.1 %)CCS-class -\|13(20.0 %)NYHA-class -\|\
 -\|\|\
 -\|\|\|50\
14\
1(76.9 %)\
(21.5 %)\
(1.5 %)*BMI* Body mass index, *ICD* Implantable cardioverter-defibrillator, *ASA* acetylsalicylic acid, *ACE* Angiotensin converting enzyme, *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass graft, *LAD* left anterior descending artery, *CCS* Canadian Cardiovascular Society Functional Classification of Angina Pectoris, *NYHA* New York Heart Association, *VO* ~*2*~ *peak* ~*BW*~ peak rate of oxygen consumption per kilogram of body mass, *VO* ~*2*~ *peak* ~*FFM*~ peak rate of oxygen consumption per kilogram of fat free body mass

No differences were found in patient characteristics between patients with or without a successful CPET or CFR measurement.

Coronary flow reserve and echocardiography {#Sec10}
------------------------------------------

Median CFR was 2.28 (1.91-2.61) and median LVEF was 54 % (47--59). There was no significant difference in CFR in participants with and without an ischemic etiology involving the LAD, by NYHA-class or gender. Table [2](#Tab2){ref-type="table"} shows measures of echocardiography, exercise capacity, glucose metabolism and body composition by CFR above and below the median CFR. Patients with a high CFR had a higher VO~2~peak~FFM~ (*P* = 0.0008) and a lower body fat percentage (*P* = 0.02). Results from univariate regression on CFR are presented in Table [3](#Tab3){ref-type="table"} and confirms a strong association between CFR and VO~2~peak~FFM~ (*p* = 0.0007).Table 2Patient´s measurements divided into "low" or "high" groups according to median CFR and VO~2~peak~FFM~Coronary flow reserveVO~2~Peak~FFM~Low (CFR ≤ 2.28)High (CFR \> 2.28)Low (VO~2~Peak~FFM~ ≤ 126.5)High (VO~2~Peak~FFM~ \>126.5)*n* = 32*n* = 33*n* = 32*n* = 33Patient characteristics Age64(59--68)62(56--67)65(61--69)62(55--65)\* Male sex26(81.3 %)28(84.9 %)24(75.0 %)30(90.9 %) CABG/PCI involving LAD16(50.0 %)20(60.0 %)19(59.4 %)17(51.5 %) ACE--inhibitors16(50.0 %)13(39.4 %)16(50.0 %)13(39.4 %) Beta--blockers17(53.1 %)17(51.5 %)17(53.1 %)17(51.5 %)Echocardiography Left ventricular ejection fraction (%)53(45--59)56(48--60)54(46--58)55(47--61) End diastolic volume (mL/m^2^)38.4(34.4--50.5)40.8(34.5--47.7)36.0(31.3--39.6)43.6(39.2--54.1)\* End systolic volume (mL/m^2^)17.6(15.0--26.6)17.7(14.2--24.3)16.4(13.8--22.0)18.5(15.6--27.0)\* Coronary flow reserve (ratio)1.91(1.77--2.09)2.62(2.53--2.97)\*2.13(1.87--2.55)2.52(2.07--2.71)\*Exercise capacity VO~2~peak~BW~ (ml/min/kg)18.3(16.5--21.9)23.2(20.5--27.3)\*17.7(16.0--20.5)25.1(22.3--27.6)\* VO~2~peak~FFM~ (ml/min/kg FFM^(2/3)^)116.0(104.0--129.9)135.5(121.6--161.9)\*108.7(98.4--119.6)145.6(133.1--162.7)\* Respiratory exchange ratio (RER)1.21(1.16--1.28)1.19(1.15--1.22)1.21(1.15--1.28)1.18(1.15--1.23)Glucose metabolism Insulin sensitivity (ISI~composite~)2.21(1.71--3.50)2.49(1.76--3.59)2.28(1.88--3.35)2.48(1.66--3.77) Insulin sensitivity (ISI~HOMA~)0.28(0.19--0.46)0.31(0.22--0.46)0.28(0.19--0.45)0.30(0.22--0.48) Hba1c (%)5.9(5.7--6.1)5.9(5.5--6.2)6.1(5.9--6.3)5.8(5.5--6.0)\* Fasting plasma glucose (mmol/L)5.88(5.31--6.33)5.85(5.65--6.18)6.07(5.70--6.33)5.73(5.46--6.07)\* Fasting plasma insulin (pmol/L)100(60--131)88(56--120)94(60--124)93(61--121) Glucose tolerance (2 h-PG) (mmol/L)7.95(6.31--9.49)7.37(5.91--8.86)8.14(6.47--9.66)7.17(5.64--8.85) Beta cell function (B~total~) (nL/kg/min)1.90(1.46--2.37)1.93(1.46--2.86)1.85(1.45--2.37)1.99(1.46--2.71) β-cell function adjusted for insulin sensitivity (D~i~)4.89(2.82--8.12)5.52(3.18--7.45)5.48(3.06--8.98)4.64(2.82--7.17)Body composition BMI (kg/m^2^)31.1(29.5--35.1)31.5(29.9--33.3)31.0(29.5--33.2)31.8(29.9--33.7) Waist-to-hip-ratio1.00(0.98--1.03)1.01(0.97--1.04)1.00(0.96--1.05)1.00(0.97--1.03) Body fat (%)35.7(32.6--41.0)32.2(29.1--35.7)\*34.3(31.0--42.1)33.4(30.5--35.8) Visceral fat (mm^3^)293(260--332)(*n* = 14)276(211--316)(*n* = 23)293(222--345)(*n* = 16)280(211--297)(*n* = 21) Central-to-peripheral fat ratio1.52(1.34--1.70)1.65(1.39--2.05)1.54(1.34--1.82)1.59(1.39--1.89)*VO* ~*2*~ *peak* ~*FFM*~ peak rate of oxygen consumption per kilogram of fat free body mass, *CABG* coronary artery bypass graft, *PCI* percutaneous coronary intervention, *LAD* left anterior descending artery, *D* ~*i*~ disposition index, *BMI* Body mass index, *VO* ~*2*~ *peak* ~*BW*~ peak rate of oxygen consumption per kilogram of body mass. \**p* \< 0.05Table 3Univariate analysis of correlations to CFR and VO~2~peak~FFM~Univariate correlationsCoronary flow reserveVO~2~Peak~FFM~r*p*-valuer*p*-valueAge−0.130.30−0.380.0015EchocardiographyLeft ventricular ejection fraction (%)0.200.100.330.008End diastolic volume (mL/m^2^)−0.060.610.320.01End systolic volume (mL/m^2^)−0.100.440.130.30Coronary flow reserve (ratio)\--0.410.0007Exercise capacityVO~2~peak~FFM~ (ml/min/kg FFM^(2/3)^)0.410.0007\--Respiratory exchange ratio (ratio)−0.170.17−0.080.52Glucose metabolismInsulin sensitivity (ISI~composite~)0.040.730.080.53Insulin sensitivity (ISI~HOMA~)0.060.650.160.18Hba1c (%)0.030.79−0.300.014Fasting plasma glucose (mmol/L)−0.060.64−0.220.08Fasting plasma insulin (pmol/L)−0.160.20−0.100.46Glucose tolerance (2 h-PG) (mmol/L)−0.200.09−0.200.10Beta cell function - B~total~ (nL/kg/min)0.110.36−0.030.84β-cell function adjusted for insulin sensitivity (D~i~)0.230.070.080.56Body compositionBMI (kg/m^2^)−0.150.22−0.050.67Waist-to-hip-ratio0.070.590.020.88Body fat (%)−0.210.09−0.290.02Visceral fat (mm^3^) (*n* = 37)−0.220.17−0.280.10Central-to-peripheral fat ratio0.130.30−0.180.16*VO* ~2~ *peak* ~*FFM*~ peak rate of oxygen consumption per kilogram of fat free body mass, *D* ~*i*~ disposition index, *BMI* Body mass index

Insulin sensitivity, as defined by the parameters ISI~HOMA~ and ISI~Composite~ showed no association with CFR. Neither did β-cell function (β~total~), nor glucose tolerance as defined by 2 h-PG. However, when grouping participants by impaired coronary microvascular function (defined as CFR \< 2) or not, glucose tolerance was significantly worse in participants with impaired coronary microvascular function (*p* = 0.008).

Exercise capacity {#Sec11}
-----------------

Though not significant, the patients had lower than predicted exercise capacity with a median VO~2~peak~bw~ of 21.3 mL/min/kg (17.5-25.1) and a median VO~2~peak % of predicted of 93.9 % (*p* = 0.12). RER values indicated that participants performed a satisfactory CPET. Table [2](#Tab2){ref-type="table"} compares echocardiographic measures, measures of glucose metabolism and body composition across patients with low and high exercise capacity dichotomized by median VO~2~peak~FFM~. Patients with a higher exercise capacity were younger, had larger left ventricular volumes and better CFR (Table [2](#Tab2){ref-type="table"}).

Measures of glucose metabolism were numerically better in the patients with higher VO~2~peak~FFM~ but only for FPG and Hba1c did the difference reach statistical significance (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). As expected, HOMA-IR, ISI~Composite~ and D~i~ were, along with the glucose and insulin measurements on which they were calculated, significantly correlated with Hba1c, MCRi and visceral fat while the correlation to body fat percentage was borderline-significant (data not shown). In general participants with high VO~2~peak~FFM~ had a lower body fat percentage, less visceral fat and less abdominal fat (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). Only body fat percentage reached statistical significance; however, only 37 patients underwent MRI.

Results of univariate linear regression analyses in relation to VO~2~peak~FFM~ are presented in Table [3](#Tab3){ref-type="table"}. VO~2~peak~FFM~ was significantly correlated with LVEF, CFR, EDV, and Hba1c. VO~2~peak~BW~ showed similar correlations.

Independent predictors of VO~2~peak were identified using a multivariable regression model presented in Table [4](#Tab4){ref-type="table"}. Age and gender, which are traditional predictors VO~2~peak, were included along with the significant correlates from the univariate analysis presented in Table [3](#Tab3){ref-type="table"}. CFR, LVEF and EDV remained independent predictors of exercise capacity while Hba1c was no longer significant.Table 4Multivariable linear regression with VO2peak as the dependent variableVO~2~peak~FFM~VO~2~peak~BW~SC*p*-valueSC*p*-valueAge−0.140.204Age−0.080.370Male sex0.170.226Male sex0.010.901Body fat %−0.010.951Body fat %−0.400.002Coronary flow reserve (ratio)0.320.003Coronary flow reserve (ratio)0.290.002Left ventricular ejection fraction (%)0.370.001Left ventricular ejection fraction (%)0.320.001Left ventricular end diastolic volume (mL/m^2^)0.330.005Left ventricular end diastolic volume (mL/m^2^)0.290.005Hb1ac (%)−0.180.075Hb1ac (%)−0.170.063*SC* Standardized coefficient, *VO* ~*2*~ *peak* ~*FFM*~ peak rate of oxygen consumption per kilogram of fat free body mass, *VO* ~*2*~ *peak* ~*BW*~ peak rate of oxygen consumption per kilogram of body mass. Respectively 48 % and 59 % of the variance of VO~2~peak~FFM~ and VO~2~peak~BW~ was explained by the included variables

ACE-inhibitors and beta-blockers can influence exercise capacity and CFR. The distribution of these medications between participants with high and low CFR and high and low VO~2~peak~FFM~ is shown in Table [2](#Tab2){ref-type="table"}. There were no significant differences. Adjustment for the use of beta-blockers and/or ACE-inhibitors did not affect the association between CFR and VO~2~peak~FFM~.

CFR measurement is performed in the LAD. Adjustment for involvement of LAD (PCI, CABG or MI) and limiting analyses to patients with no involvement of the LAD did not affect estimates. Figure [1](#Fig1){ref-type="fig"} shows scatterplots with linear regression lines between VO~2~peak~FFM~ and CFR and VO~2~peak~FFM~ and LVEF. Results were similar when using VO~2~peak~BW~ as the dependent variable.Fig. 1Scatter plots with linear regression lines and confidence interval (CI) between VO~2~peak~FFM~ and CFR (left) and VO~2~peak~FFM~ and LVEF (right)

Discussion {#Sec12}
==========

The present study is the first to investigate the effect of glucose metabolism and body composition on coronary microvascular function and exercise capacity in non-diabetic overweight patients with CAD. Our results confirm a strong association between coronary microvascular function and exercise capacity, but indicate that the role of glucose metabolism and body composition is limited in non-diabetic, overweight CAD patients and that the reduced exercise capacity is primarily determined by other parameters.

Microvascular function {#Sec13}
----------------------

Two studies found a correlation between insulin sensitivity measured by the hyperinsulinemic-euglycemic clamp technique and CFR in heart failure patients (*n* = 39) \[[@CR7]\] and in obese subjects (*n* = 36 ) \[[@CR19]\], respectively. A study including non-diabetic women with suspected CAD but angiographically normal coronary arteries (*n* = 45) found a correlation between CFR and insulin resistance using an OGTT \[[@CR20]\]. In the present study insulin sensitivity and appropriate β-cell function as measured by disposition index were congruent with higher CFR, but associations were non-significant. This may be due to the methods used. In the present study insulin sensitivity was evaluated by an OGTT with 13 plasma samples obtained over a 3 hour period. The clamp technique is considered to be the gold standard, however, all indices from the OGTT have been validated against the clamp technique and are regarded as valid measures \[[@CR13], [@CR14]\]. Also, the oral test may be considered more physiologic than the intravenous clamp technique by activating the important incretin effects. However, when considering the glucose tolerance in those 40 % of patients who by definition display impaired CFR (\<2.0) they displayed a highly significant impaired glucose tolerance compared to those 60 % of patients with normal CFR. Thus data available from previous studies and the present study appear slightly inconsistent, but notably the number of studies is limited.

CFR is a measure of coronary microvascular function and body composition has previously been linked to peripheral endothelial function \[[@CR21]\] and the endothelium-related myocardial blood flow response as measured by PET (*n* = 111) \[[@CR22]\]. Therefore an association between CFR and body composition could be expected. Participants with low CFR had a significantly higher body fat percentage; however, the measures of body composition were not associated with CFR in the regression analyses. Only 37 participants underwent MRI and consequently the study may have been under-powered to assess associations between visceral fat and CFR.

Exercise capacity {#Sec14}
-----------------

The achieved respiratory exchange ratios achieved during exercise testing indicate that all patients delivered a satisfactory CPET. The equal median RER-values in the groups of high and low exercise capacity further accentuate that the VO~2~peak~FFM~ was not influenced by exercise effort.

HbA1c and FPG demonstrated significant inverse associations to VO~2~peak~FFM~ and estimates of insulin sensitivity, glucose tolerance and β-cell function showed a trend to associate to better exercise capacity. These findings are only partly in concordance with previous studies. Studies evaluating the correlation of exercise capacity and insulin sensitivity using the glucose clamp technique in a healthy population (*n* = 20 ) \[[@CR23]\] and heart failure patients (*n* = 39 and *n* = 9 , respectively) \[[@CR7], [@CR24]\] reported an association between insulin sensitivity and VO~2~peak. A recent study of 170 patients with CAD and diabetes also found VO~2~peak to be correlated with HOMA-IR but not with FPG or Hba1c \[[@CR25]\] while another study evaluating the effect of exercise training in a similar population found a correlation between baseline FPG and Hba1c and VO~2~peak but not between HOMA-IR and VO~2~peak \[[@CR26]\].

Thus, our results indicate that the effect of the glucose metabolism on coronary microvascular function is limited and does not explain the previously observed link between CFR and exercise capacity in CAD patients without diabetes. In this group of patients, exercise capacity was primarily determined by other parameters than body composition and glucose metabolism. These parameters included left ventricular ejection fraction and end diastolic volume.

Although cardiac output is defined by stroke volume, which in turn is determined by end diastolic volume and ejection fraction, previous studies have not found this straight-forward association. A large study investigating the relationship in patients with a clinical indication for exercise echocardiography, no exercise-induced myocardial ischemia and LVEF \> 50 % found no correlation between LVEF and exercise capacity \[[@CR27]\]. However, exercise capacity was calculated from the exercise echocardiography using metabolic equivalents, which is less accurate compared to the CPET used in the present study. Most studies in heart failure patients found little or no association between LVEF and VO~2~peak \[[@CR18], [@CR28], [@CR29]\] whereas a study investigating the relationship in asymptomatic CAD patients (*n* = 27) described a correlation between peak LVEF and exercise capacity \[[@CR30]\].

Like previous studies in healthy subjects \[[@CR31], [@CR32]\], heart failure patients \[[@CR7], [@CR18]\] and CAD patients \[[@CR6]\], we found a strong correlation between CFR and exercise capacity. Exercise capacity is a strong prognostic marker in patients with CAD \[[@CR1]\] and it has been demonstrated that exercise training can improve coronary endothelial function in CAD patients \[[@CR33]\]. In this study population consisting of overweight CAD patients with a LVEF \> 35 % and primarily NYHA class I or II, CFR remained an independent predictor of VO~2~peak~FFM~ in the multivariable linear regression analysis alongside LVEF and EDV. This is, to our knowledge, the largest study evaluating the correlation of CFR and exercise capacity and the first study establishing CFR and LVEF to be independent predictors of VO~2~peak.

Conclusion {#Sec15}
==========

The study established that coronary microvascular function and LVEF are independent predictors of VO~2~peak in overweight CAD patients with no or only mild functional symptoms and a LVEF \> 35 %. Glucose metabolism and body composition were weak determinants of exercise capacity and did not contribute significantly to explain the link between CFR and exercise capacity. The findings suggest that central hemodynamic factors are important in limiting exercise capacity in overweight non-diabetic CAD patients.

CAD

:   coronary artery disease

LVEF

:   left ventricular ejection fraction

CFR

:   coronary flow reserve

EDV

:   end-diastolic volume

LED

:   low energy diet

CPET

:   cardiopulmonary exercise test

RER

:   respiratory exchange ratio

BW

:   body weight

FFM

:   fat free mass

DEXA

:   dual-energy X-ray absorptiometry

MRI

:   magnetic resonance imaging

OGTT

:   oral glucose tolerance test

FPG

:   fasting plasma glucose

FPI

:   Fasting plasma insulin

2 h-PG

:   2-hour plasma glucose

ISI~composite~

:   composite measure of whole body insulin sensitivity

HOMA-IR

:   homeostatis model assessment of hepatic insulin resistance

ISR

:   insulin secretion rates

β~total~

:   β-cell responsiveness

Di

:   disposition index

ESV

:   end-systolic volume

LAD

:   left anterior descending artery

SC

:   standardized coefficients

BMI

:   body mass index

ICD

:   implantable cardioverter-defibrillator

ASA

:   acetylsalicylic acid

ACE

:   angiotensin converting enzyme

PCI

:   percutaneous coronary intervention

CABG

:   coronary artery bypass graft

CCS

:   Canadian Cardiovascular Society Functional Classification of Angina Pectoris

NYHA

:   New York Heart Association
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